Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study is composed of 2 parts. In Part A, approximately 3-6 participants are expected to be enrolled to confirm the tolerability in Chinese participants. If deemed safe, the enrollment of Part B will proceed to include a total of approximately 9 participants in the study to continue to evaluate the pharmacokinetics, safety and preliminary efficacy of single agent PF-07901801 (Maplirpacept).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed relapsed/refractory non-Hodgkin lymphoma without other effective therapeutic option. Or relapsed/refractory multiple myeloma exposed to therapies including PI, IMiD and anti-CD38 antibody.
With measurable disease
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
Adequate organ functions (including hematologic status, coagulation, hepatic, and renal)
You may not be if
Active plasma cell leukemia, or POEMS syndrome.
Known, current central nervous system disease involvement.
Significant cardiovascular disease.
Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent.
Radiation therapy within 14 days of study treatment administration.
Hematopoietic stem cell transplant within 90 days before the planned start of study treatment or participants with active GVHD disease.
Use of any anticancer drug within 14 days before planned start of study treatment.
Prior anti-CD47 or anti-SIRP alpha therapy.
Participation in other studies involving investigational drug(s) or vaccines within 4 weeks from the last dose
Known active, uncontrolled bacterial, fungal, or viral infection.